Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
27401327
DOI
10.1016/j.jconrel.2016.07.012
PII: S0168-3659(16)30446-1
Knihovny.cz E-resources
- Keywords
- Core-crosslinking, Drug release, Drug targeting, Nanomedicine, Polymeric micelles,
- MeSH
- Acrylamides chemistry MeSH
- Docetaxel MeSH
- Doxorubicin chemistry MeSH
- Micelles * MeSH
- Molecular Weight MeSH
- Drug Carriers chemistry MeSH
- Polymers chemistry MeSH
- Cross-Linking Reagents chemistry MeSH
- Taxoids chemistry MeSH
- Drug Liberation MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Acrylamides MeSH
- Docetaxel MeSH
- Doxorubicin MeSH
- Micelles * MeSH
- N-(2-hydroxypropyl)methacrylamide MeSH Browser
- Drug Carriers MeSH
- Polymers MeSH
- Cross-Linking Reagents MeSH
- Taxoids MeSH
To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn (i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100nm), nanocarrier degradation (1month to 1year) and drug release kinetics (10 to 90% in 1week). This was achieved by modulating the molecular weight of the block copolymer, the type and density of the crosslinking agent, and the hydrolytic sensitivity of the drug linkage, respectively. The high flexibility of CCPM facilitates the development of nanomedicinal products for specific therapeutic applications.
References provided by Crossref.org
